InterVenn BioSciences, a Redwood City, Calif.-based life sciences and technology company developing an AI-driven mass spectrometry platform, raised $9.4m in funding.
The round was led by biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV. In conjunction with the funding, Jenny Rooke, Ph.D., founder and managing director at Genoa Ventures, and Adam D’Augelli, partner at True Ventures, will join InterVenn’s board of directors. Sunil Dhaliwal, general partner at Amplify Partners, will join as a board observer.
The company intends to use the funds to develop its first product, a blood-based ovarian cancer diagnostic.
Led by Aldo Carrascoso, CEO, InterVenn leverages mass spectrometry, hi-res characterization of post-translational modifications, and artificial intelligence, to streamline and expedite Glycoproteomics (an emerging field combining proteomics and glycomics, which can help with better biomarker and target discovery, and produces an enormous amount of data in minutes), and ensure that any variability in the workflow–from the sample collection, processing, and all the way to instrument ingestion– is minimized and the results reproducible.
The company’s first product is a blood-based ovarian cancer diagnostic that is currently undergoing analytical and clinical validation. Once the validation and regulatory processes are completed, the company will begin offering a laboratory diagnostic test.